Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I0JG
|
|||
| Former ID |
DIB018291
|
|||
| Drug Name |
[3H]fenobam
|
|||
| Synonyms |
57653-26-6; 3-(3-chlorophenyl)-1-(1-methyl-4-oxo-5H-imidazol-2-yl)urea; SMR001456387; MLS006011708; ZINC1436; GTPL1434; GTPL1433; 1-(3-chlorophenyl)-3-(1-methyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl)urea; CTK8F9740; CTK5B9436; DWPQODZAOSWNHB-UHFFFAOYSA-N; LP00842; NCGC00092384-04; FT-0630701
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Allodynia [ICD-11: MB40.1] | Phase 1 | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C11H11ClN4O2
|
|||
| Canonical SMILES |
CN1CC(=O)NC1=NC(=O)NC2=CC(=CC=C2)Cl
|
|||
| InChI |
1S/C11H11ClN4O2/c1-16-6-9(17)14-10(16)15-11(18)13-8-4-2-3-7(12)5-8/h2-5H,6H2,1H3,(H2,13,14,15,17,18)
|
|||
| InChIKey |
DWPQODZAOSWNHB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 57653-26-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7698550, 10255018, 12015575, 15368151, 24894721, 26753296, 46237428, 50076506, 57350010, 79662796, 85209784, 85788195, 90341711, 90438823, 103088281, 103088282, 103156738, 103156739, 103546087, 104081432, 113450413, 117595975, 121324203, 121361629, 134221954, 135116692, 135650255, 135651153, 135697547, 136309293, 137133037, 144206177, 144207065, 162023388, 162221725, 162887753, 163134645, 163564796, 164175140, 164814496, 167250227, 170466272, 174006275, 175612574, 177513142, 179150698, 184546104, 198946610, 216088083, 223704488
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Metabotropic glutamate receptor 5 (mGluR5) | Target Info | Modulator (allosteric modulator) | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Long-term potentiation | ||||
| Retrograde endocannabinoid signaling | ||||
| Glutamatergic synapse | ||||
| Huntington's disease | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||
| Metabotropic glutamate receptor group III pathway | ||||
| Metabotropic glutamate receptor group I pathway | ||||
| Endogenous cannabinoid signaling | ||||
| Reactome | G alpha (q) signalling events | |||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
| WikiPathways | Hypothetical Network for Drug Addiction | |||
| GPCRs, Class C Metabotropic glutamate, pheromone | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01981395) Fenobam on Heat/Capsaicin Induced Hyperalgesia in Healthy Volunteers. U.S. National Institutes of Health. | |||
| REF 2 | Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agon... J Pharmacol Exp Ther. 2005 Nov;315(2):711-21. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.